Lineage Cell Therapeutics Inc. Logo

Lineage Cell Therapeutics Inc.

Developing off-the-shelf cell therapies for neurological and ophthalmic conditions.

LCTX | TA

Overview

Corporate Details

ISIN(s):
US53566P1093
LEI:
Country:
Israel
Address:
Derech Menachem Begin 121, 6701203 Tel Aviv
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel allogeneic ("off-the-shelf") cell therapies for serious neurological and ophthalmic conditions. The company's proprietary platform utilizes directed differentiation processes on pluripotent cell lines to manufacture specialized human cells. These cells are designed to be transplanted into patients to replace or support cells that are absent or dysfunctional due to degenerative disease, aging, or traumatic injury, with the goal of restoring functional activity. Lineage leverages its technology and manufacturing capabilities to advance its programs internally and through strategic partnerships.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-08 20:22
Regulatory News Service
Immediate Report
English 30.9 KB
2025-09-08 20:22
Foreign Filer Report
Immediate Report
English 36.5 KB
2025-08-13 11:32
Earnings Release
Second Quarter 2025 Financial Results and Provides Business Update
English 69.6 KB
2025-08-13 11:32
Foreign Filer Report
Second Quarter 2025 Financial Results and Provides Business Update
English 36.5 KB
2025-07-03 15:05
Director's Dealing
FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP - Jayasuriya Anula
Hebrew (modern) 117.3 KB
2025-07-03 15:05
Foreign Filer Report
FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP - Jayasuriya Anula
English 36.6 KB
2025-07-03 15:00
Director's Dealing
FORM4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP - Mulroy Michael H.
Hebrew (modern) 117.7 KB
2025-07-03 15:00
Major Shareholding Notification
FORM4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP - Mulroy Michael H.
English 36.5 KB
2025-07-03 14:55
Post-Annual General Meeting Information
FORM 8-K-The Annual Meeting - final voting results
Hebrew (modern) 128.3 KB
2025-07-03 14:55
Declaration of Voting Results & Voting Rights Announcements
FORM 8-K-The Annual Meeting - final voting results
English 36.5 KB
2025-06-23 20:53
Proxy Solicitation & Information Statement
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS To Be Held June 26, 2025
English 2.8 MB
2025-06-23 20:53
Foreign Filer Report
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS To Be Held June 26, 2025
English 36.5 KB
2025-05-14 12:01
Earnings Release
First Quarter 2025 Financial Results and Provides Business Update
English 64.9 KB
2025-05-14 12:01
Report Publication Announcement
First Quarter 2025 Financial Results and Provides Business Update
English 36.5 KB
2025-05-14 11:23
Regulatory News Service
The company's financial results for the First quarter of 2025 were reported abr…
Hebrew (modern) 82.6 KB

Automate Your Workflow. Get a real-time feed of all Lineage Cell Therapeutics Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Lineage Cell Therapeutics Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.